Efficacy of canagliflozin versus liraglutide, alternative to bolus insulin in patients with basal-bolus regimen. - Efficacy of canagliflozin versus liraglutide, alternative to bolus insulin in patients with basal-bolus regimen (ECLIPS).

Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Toho University School of Medicine0 个研究点目标入组 40 人开始时间: 2015年10月16日最近更新: 2023年10月17日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 40

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 20years-old 至 ot applicable（—）
性别: All

入选标准

未提供

排除标准

•(1) Type 1 diabetes mellitus patients or steroid induced diabetes mellitus. (2) Patients with aspartate aminotransferase or alanine aminotransferase more than 100 IU/L. (3) Patients with plasma creatinine more than 2.0mg/dL. (4) Patients who had myocardial infarction within 3 months. (5) Patients with severe pancreas disease (6) Patients taking cancer treatment (7) Patients with hemoglobin (Hb) less than 11 g/dL. (8) Patients whose the number of the platelets is less than 100,000 /mm3. (9) Patients with severe diabetic neuropathy (10) Patients having proliferative retinopathy. (11) Patients with serious infectious disease or operative state. (12) Patients with inflammatory bowel disease and chronic bowel disease. (13) Heavy alcohol drinkers. (14) Patients who are pregnant, hope to be pregnant, or are in lactation period. (15) Patients with positive of HBV or HCV. (16) In addition, the patients who will be judged inappropriate by an attendant physician.

研究者

发起方

Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Toho University School of Medicine

相似试验

已完成

4 期

A clinical trial to compare the effects of Canagliflozin and Sitagliptin in Patients with Type 2 Diabetes mellitus on a background metformin therapy.

CTRI/2019/02/017435SRM College of Pharmacy40

已完成

不适用

Comparison of canagliflozin vs. tenegliptin against basic metabolic risks in patients with type 2 diabetes mellitusT2DM patients with basic metabolic risks

JPRN-UMIN000030343ational Cerebral and Cardiovascular Center200

尚未招募

不适用

Effect of canagliflozin as an alternative drug from DPP-4 inhibitor on heart failure with diabetis melltus : the pilot study "Can canagliflozin HAve Not only hypoGlycemic but cardiac supportive Effect?"chronic heart failure with type 2 diabetis mellitus

JPRN-UMIN000031563Osaka Rosai Hospital40

进行中（未招募）

1 期

Efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in subjects with type 2 diabetesMedDRA version: 16.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 100000004861Diabetes Mellitus, Type 2

EUCTR2012-004984-27-GBovo Nordisk A/S404

进行中（未招募）

不适用

Efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in subjects with type 2 diabetesMedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 2

EUCTR2012-004984-27-FIovo Nordisk A/S400